Quantinno Capital Management’s Bright Minds Biosciences DRUG Stock Holding History

Quantinno Capital Management’s Portfolio DRUG Stock Details DRUG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$812K	Buy	+16,300	New	+$1.15M	﹤0.01%	2927

Other funds holding DRUG

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

AdvisorShares Investments Bethesda, Maryland $796M AUM 17.24% 1-Year Est. Return

Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return

Quadrature Capital London, United Kingdom $16.1B AUM 61.25% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Quantinno Capital Management's DRUG Position: Q3 2026 in Review

Quantinno Capital Management opened a new position in Bright Minds Biosciences (DRUG) in Q3 2026: 16,300 shares worth $812K. The stake represents ﹤0.01% of the portfolio and ranks #2927 among its holdings.

49 funds tracked by Wall St. Rank hold DRUG as of Q3 2026.

Quantinno Capital Management held 16,300 shares of Bright Minds Biosciences worth $812K as of Q3 2026.
Bright Minds Biosciences was a new Quantinno Capital Management position in Q3 2026.
Bright Minds Biosciences made up ﹤0.01% of Quantinno Capital Management's portfolio in Q3 2026, its #2927 holding.
49 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q3 2026.

Based on Quantinno Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.